DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1158 Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking
and treatment outcomes in Graves’ ophthalmopathy. Ann
Intern Med, 1998b, 129:632–635.
Barwell J, Fox GF, Round J, Berg, J. Choanal atresia: The result
of maternal thyrotoxicosis or fetal carbimazole? Am J Med
Genet, 2002, 111:55–56.
Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med,
2005, 118:706–714.
Bassett JH, Harvey CB, Williams GR. Mechanisms of thyroid
hormone receptor-specific nuclear and extra nuclear actions.
Mol Cell Endocrinol, 2003, 213:1–11.
Baxter JD, Webb P. Thyroid hormone mimetics: Potential applications
in atherosclerosis, obesity and type 2 diabetes. Nat Rev
Drug Discov, 2009, 8:308–320.
Becker DV, Braverman LE, DeLange F, et al. Iodine supplementation
for pregnancy and lactation—United States and Canada:
Recommendations of the American Thyroid Association.
Thyroid, 2006, 16:949–951.
Bernal J. Thyroid hormone receptors in brain development and
function. Nat Clin Pract Endocrinol Metab, 2007, 3:249–259.
Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular
and molecular biology, and physiological roles of the
iodothyronine selenodeiodinases. Endocr Rev, 2002, 23:
38–89.
Biondi B, Cooper DS. Clinical significance of subclinical thyroid
dysfunction. Endocr Rev, 2008, 29:76–131.
Blount BC, Pirkle JL, Osterloh JD, et al. Urinary perchlorate and
thyroid hormone levels in adolescent and adult men and
women living in the United States. Environ Health Perspect,
2006, 114:1865–1871.
Braverman LE, Ingbar SH, Sterling K. Conversion of thyroxine
(T4) to triiodothyronine (T3) in athyreotic human subjects.
J Clin Invest, 1970, 49:855–864.
Brent GA. Graves’ disease. N Engl J Med, 2008, 358:2594–2605.
Brenta G, Danzi S, Klein I. Potential therapeutic applications of
thyroid hormone analogs. Nat Clin Pract Endocrinol Metab,
2007, 3:632–640.
Burman KD, Hennessey J, McDermott M, et al. The FDA revises
requirements for levothyroxine products. Thyroid, 2008,
18:487–490.
Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH.
Levothyroxine dose requirements for thyrotropin suppression
in the treatment of differentiated thyroid cancer. J Clin
Endocrinol Metab, 1992, 75:344–350.
Cao XY, Jiang XM, Dou ZH, et al. Timing of vulnerability of
the brain to iodine deficiency in endemic cretinism. N Engl J
Med, 1994, 331:1739–1744.
Carvalho AF, Cavalcante JL, Castelo MS, Lima MC.
Augmentation strategies for treatment-resistant depression: A
literature review. J Clin Pharm Ther, 2007, 32:415–428.
Chan GW, Mandel SJ. Therapy insights: Management of Graves’
disease during pregnancy. Nat Clin Pract Endocrinol Metab,
2007, 3:470–478.
Charnley G. Perchlorate: Overview of risks and regulations.
Food Chem Toxicol, 2008, 46:2307–2315.
Chiamolera MI, Wondisford FE. Minireview: Thyrotropinreleasing
hormone and the thyroid hormone feedback mechanism.
Endocrinology, 2009, 150:1091–1096.
Cooper DS. Antithyroid drugs in the management of patients with
Graves’ disease: An evidence-based approach to therapeutic
controversies. J Clin Endocrinol Metab, 2003, 88:3474–3481.
SECTION V
HORMONES AND HORMONE ANTAGONISTS
Cooper DS. Antithyroid drugs. N Engl J Med, 2005, 352: 905–917.
Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines
for patients with thyroid nodules and differentiated thyroid
cancer. Thyroid, 2006, 16:109–142.
Cooper DS, Rivkees S. Putting propylthiouracil in perspective.
J Clin Endocrinol Metab, 2009, 94:1881–1882.
Cooper-Kazaz R, van der Deure WM, Medici M, et al.
Preliminary evidence that a functional polymorphism in type
1 deiodinase is associated with enhanced potentiation of the
antidepressant effect of sertraline by triiodothyronine. J Affect
Disord, 2009, 116:113–116.
Crunkhorn S, Patti ME. Links between thyroid hormone action,
oxidative metabolism, and diabetes risk? Thyroid, 2008,
18:227–237.
Davis PJ, Leonard JL, Davis FB. Mechanisms of nongenomic
actions of thyroid hormone. Front Neuroendocrinol, 2008,
29:211–218.
de Vathaire F, Schlumberger M, Delisle MJ, et al. Leukaemias
and cancers following iodine-131 administration for thyroid
cancer. Br J Cancer, 1997, 75:734–739.
Demers LM, Spencer CA. Laboratory medicine practice guidelines:
Laboratory support for the diagnosis and monitoring of
thyroid disease. Clin Endocrinol (Oxf), 2003, 58:138–140.
Di Cosmo C, Liao X, Dumitrescu AM, et al. A thyroid hormone
analog with reduced dependence on the monocarboxylate
transporter 8 for tissue transport. Endocrinology, 2009,
150:4450–4458.
Diamanti-Kandarakis E, Boruguignon J-P, Giudice LC, et al.
Endocrine-disrupting chemicals: An Endocrine Society scientific
statement. Endocr Rev, 2009, 30:293–342.
Diav-Citrin O, Ornoy A. Teratogen update: Antithyroid drugsmethimazole,
carbimazole, and propylthiouracil. Teratology,
2002, 65:38–44.
Dohan O, De la Vieja A, Paroder V, et al. The sodium/iodide
symporter (NIS): characterization, regulation, and medical significance.
Endocr Rev, 2003, 24:48–77.
Dohan O, Portulano C, Basquin C, et al. The Na+/I-symporter
(NIS) mediates electroneutral active transport of the environmental
pollutant perchlorate. Proc Natl Acad Sci USA, 2007,
104:20250–20255.
Dottorini ME, Lomuscio G, Mazzucchelli L, et al. Assessment of
female fertility and carcinogenesis after iodine-131 therapy for
differentiated thyroid carcinoma. J Nucl Med, 1995, 36:21–27.
Doyle KP, Suchland KL, Ciesielski TM, et al. Novel thyroxine
derivatives, thyronamine and 3-iodothyronamine, induce transient
hypothermia and marked neuroprotection against stroke
injury. Stroke, 2007, 38:2569–2576.
Dumitrescu AM, Liao XH, Abdullah MS, et al. Mutations in
SECISBP2 result in abnormal thyroid hormone metabolism.
Nat Genet, 2005, 37:1247–1252.
Dunn JT, Dunn AD. Update on intrathyroidal iodine metabolism.
Thyroid, 2001, 11:407–414.
Duntas LH, Cooper DS. Review on the occasion of a decade of
recombinant human TSH: Prospects and novel uses. Thyroid,
2008, 18:509–516.
El Fassi D, Banda JP, Gilbert JA, et al. Treatment of Graves’ disease
with rituximab specifically reduces the production of thyroid
stimulating autoantibodies. Clin Immunol, 2009, 130:
252–258.
Elnagar B, Eltom M, Karlsson FA, et al. The effects of different
doses of oral iodized oil on goiter size, urinary iodine, and